SCHEMBL8266243

SCHEMBL8266243

CCOC(=O)c1ccc(Nc2ccc(Br)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NHERF1 O14745 1/20 0.68
RAB9A P51151 5/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
THRB P10828 2/20 0.60
SLC2A1 P11166 1/20 0.60
MAPT P10636 5/20 0.58
HPGD P15428 2/20 0.58
RECQL P46063 1/20 0.58
KDM4E B2RXH2 2/20 0.57
DHODH Q02127 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
TSHR P16473 1/20 0.56
CA12 O43570 1/20 0.56
ESR1 P03372 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
ESR2 Q92731 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12124929 0.91 RAB9A (0.69) RAB9AMEN1KMT2ATHRBSLC2A1
SCHEMBL274513 0.89 CA1 (0.68) NHERF1RAB9AMEN1KMT2AMAPT
SCHEMBL2989285 0.88 CA12 (0.66) NHERF1RAB9AMEN1KMT2AMAPT
SCHEMBL1615670 0.88 CA1 (0.66) NHERF1RAB9AMEN1KMT2AMAPT
SCHEMBL9805589 0.86 NHERF1 (0.62) NHERF1RAB9AMEN1KMT2AMAPT
SCHEMBL9644563 0.86 RAB9A (0.63) RAB9AMEN1KMT2ATHRBSLC2A1
SCHEMBL9176722 0.85 SMN1; SMN2 (0.72) RAB9AMEN1KMT2ATHRBSLC2A1
SCHEMBL2270040 0.84 CA12 (0.61) NHERF1RAB9AMEN1KMT2AMAPT
Boric Acid SCHEMBL28174370 0.84 CA12 (0.61) NHERF1RAB9AMEN1KMT2AMAPT
SCHEMBL6705884 0.84 CA12 (0.61) NHERF1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-04 US disclosed
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-04 US disclosed
EP-3864030-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION The Scripps Research Institute (US) 2021-08-18 EP disclosed
US-20200190105-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION THE SCRIPPS RESEARCH INSTITUTE 2020-06-18 US disclosed
WO-2006064286-A1 CATHEPSIN S INHIBITORS MEDIVIR UK LTD (GB) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190105-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION DCAF1, CUL4A, DCAF15 NHERF1 2731/4885RAB9A 2928/4885MEN1 3057/4885
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation DCAF1, CUL4A, DCAF15 NHERF1 2731/4885RAB9A 2928/4885MEN1 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.